Castro Valley, CA, United States of America

Cornelia Bellamacina

USPTO Granted Patents = 1 


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Cornelia Bellamacina

Introduction: Cornelia Bellamacina is a remarkable inventor based in Castro Valley, CA, known for her contributions to the field of biomedical science. With a focus on cancer treatment, she has developed innovative solutions that hold promise for improving therapeutic outcomes for patients.

Latest Patents: Cornelia's most notable patent is titled "PIM kinase inhibitors and methods of their use." This patent introduces new compounds, compositions, and methods aimed at inhibiting kinase activity associated with tumorigenesis in human or animal subjects. The innovative compounds and compositions are designed to effectively inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. These new inventions can be utilized alone or in conjunction with additional agents to treat disorders linked to serine/threonine kinase or receptor tyrosine kinase, particularly cancer.

Career Highlights: Currently, Cornelia is affiliated with Novartis AG, where she continues her groundbreaking work in pharmaceutical research and development. Her expertise and dedication have contributed significantly to advancing therapeutic options in oncology.

Collaborations: Among her colleagues at Novartis AG, Cornelia collaborates closely with Matthew T. Burger and Mika Lindvall. Together, they work on cutting-edge projects that seek to enhance the understanding and treatment of kinase-mediated disorders.

Conclusion: Cornelia Bellamacina is a notable figure in the world of innovations, particularly in the realm of cancer treatment. Her patent on PIM kinase inhibitors represents a significant advancement in the fight against cancer, showcasing her commitment to improving patient outcomes through innovative research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…